Skip to main content

Table 4 Published studies on the pharmacokinetics of rivaroxaban in patients (mean)

From: Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

Patients

Demographic information

Age

Dosage

Cmax (ng•mL−1)

Ctrough (ng•mL− 1)

CL/F (L•h− 1)

Vd (L)

Undergoing total hip replacement [17]

Caucasian

27 ~ 93

10 mg qd

124.6a

9.1a

7.3

49.1

Deep venous thrombosis [18]

Caucasian

18 ~ 91

20 mg qd

270

25.5

5.67

54.4

Non-valvular atrial fibrillation [19]

Caucasian

51 ~ 92

20 mg qd

290

32

6.1

79.7

  1. amedian; −, not published